Evidence map›Paper›PMID 40054125›Full record

ArticleTranslational oncology2025

Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer.

Mallory I Frederick, Elicia Fyle, Anna Clouvel, Djihane Abdesselam, Saima Hassan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mallory I FrederickFaculty of Medicine, Université de Montréal, Montréal, QC H3C 3T5, Canada; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), l'Institut de Cancer de Montreal, Montreal, QC H2X0A9, Canada.
Elicia FyleFaculty of Medicine, Université de Montréal, Montréal, QC H3C 3T5, Canada; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), l'Institut de Cancer de Montreal, Montreal, QC H2X0A9, Canada.
Anna ClouvelCentre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), l'Institut de Cancer de Montreal, Montreal, QC H2X0A9, Canada.
Djihane AbdesselamFaculty of Medicine, Université de Montréal, Montréal, QC H3C 3T5, Canada; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), l'Institut de Cancer de Montreal, Montreal, QC H2X0A9, Canada.
Saima HassanFaculty of Medicine, Université de Montréal, Montréal, QC H3C 3T5, Canada; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), l'Institut de Cancer de Montreal, Montreal, QC H2X0A9, Canada; Division of Surgical Oncology, Department of Surgery, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X0C1, Canada. Electronic address: saima.hassan@umontreal.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. The only targeted therapeutic approach that has emerged for early TNBC patients with BRCA-mutations (BRCA

Indexed as

Combination therapyDNA damageDNA replication fork speedFEN1/EXO1 inhibitionIntrinsic and acquired resistance to PARP inhibitorPARP inhibitorTriple-negative breast cancer

Identifiers

PMID40054125
PMCPMC11928819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.